Key result
Intravenous administration of nifekalant hydrochloride at relatively low doses effectively prevented ischemia-induced ventricular tachyarrhythmias in patients with renal failure undergoing hemodialysis.
Why the study?
How should intravenous nifekalant hydrochloride be dosed and monitored in patients with renal failure undergoing hemodialysis?
Case Report (n=3)
No
How should intravenous nifekalant hydrochloride be dosed and monitored in patients with renal failure undergoing hemodialysis?
In hemodialysis patients, intravenous nifekalant hydrochloride requires dose adjustment and careful QT interval monitoring because the drug is not cleared by dialysis.
Answers are grounded in this paper and cite their sources.
May support low-dose nifekalant for VT prevention in hemodialysis; hypothesis-generating and requires prospective validation on dosing and QT monitoring.
Excretion in the urine is an important pathway for the elimination of nifekalant hydrochloride (NIF), a novel class III antiarrhythmic agent. Three patients with renal failure were undergoing hemodialysis and receiving NIF for the prevention of ischemia-induced ventricular tachyarrhythmia. Because NIF is not dialyzed, dose adjustment at relatively low concentrations was required, with monitoring of the QT interval.
No takes yet. Share an insight, caveat, or question.
Myoishi et al. (2003) conducted a case report in Renal failure undergoing hemodialysis with ischemia-induced ventricular tachyarrhythmia (n=3). Nifekalant hydrochloride was evaluated on Prevention of ischemia-induced ventricular tachyarrhythmia. Intravenous administration of nifekalant hydrochloride at relatively low doses effectively prevented ischemia-induced ventricular tachyarrhythmias in patients with renal failure undergoing hemodialysis.
Synapse has enriched 10 related papers. Consider them for comparative context: